OncoMatch/Clinical Trials/NCT06151106
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Is NCT06151106 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chidamide combined with Duvillisib for peripheral t cell lymphoma.
Treatment: Chidamide combined with Duvillisib — To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: anthracycline-containing chemotherapy — first-line
Relapsed and refractory patients who have received at least first-line systemic treatment with anthracycline-containing drugs in the past
Cannot have received: PI3K inhibitor
Exception: disease has progressed during the treatment period (within 6 months after the last use)
Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use)
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5×10^9/L, platelet ≥ 75×10^9/L, Hb ≥ 80g/L
Liver function
total bilirubin (TBiL) ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN (≤ 5 ULN if liver infiltrated by lymphoma cells)
Cardiac function
No clinically significant abnormal rhythm or conduction, hereditary QT interval syndrome, QTcF ≤ 480 msec, no drugs that may cause QT interval delay or torsade de pointes, no NYHA grade 3 or above, LVEF ≥ 40%, no uncontrolled hypertension (SBP ≤ 160 mmHg, DBP ≤ 100 mmHg), no acute MI, unstable angina, or CABG within 6 months
Routine blood examination: absolute neutrophil count ≥ 1.5× 10 9/L, platelet ≥ 75x10 9/L, Hb ≥ 80g/L. total bilirubin (TBiL) > 1.5 ULN, or AST or ALT >2.5ULN, except the following situations. if patients with liver infiltrated by lymphoma cells, AST and ALT < 5ULN could be enrolled. all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06151106 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PI3K inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages